Technology

Pharmacopeia And Eos Biotechnology To Merge

Published in Genomics and Genetics Weekly, October 5th, 2001

Privately held Eos Biotechnology Inc. will merge with Pharmacopeia Inc. (PCOP) in a tax-free, stock-for-stock transaction valued at approximately $197 million, including the value of shares to be issued upon the exercise of stock options. Included in the transaction value is $44 million cash owned by Eos.

The transaction unites Eos' drug target identification and validation expertise and therapeutic antibody development skills with Pharmacopeia's integrated small-molecule drug discovery capabilities. The combined technologies will create a powerful platform for the identification and validation of drug targets and the discovery of small-molecule and therapeutic...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Genomics and Genetics Weekly

Source: Genomics and Genetics Weekly (2001-10-05)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry